Sodium Bicarbonate → HCID 71007537, compound

HRID 1469554Notes

Reaction equation

HRID 1469554 reaction equation
[CH3:1][C:2]1[CH:10]=[CH:9][C:8]2[N:7]([CH2:11][CH:12]([C:14]3[N:18](C(C4C=CC=CC=4)(C4C=CC=CC=4)C4C=CC=CC=4)[CH:17]=[N:16][CH:15]=3)[OH:13])[C:6]3[CH2:38][CH2:39][N:40]4[CH:44]([C:5]=3[C:4]=2[CH:3]=1)[CH2:43][CH2:42][CH2:41]4.C(=O)(O)[O-].[Na+]>CO.Cl>[NH:18]1[C:14]([CH:12]([OH:13])[CH2:11][N:7]2[C:8]3[CH:9]=[CH:10][C:2]([CH3:1])=[CH:3][C:4]=3[C:5]3[CH:44]4[N:40]([CH2:39][CH2:38][C:6]2=3)[CH2:41][CH2:42][CH2:43]4)=[CH:15][N:16]=[CH:17]1

Participants

5

Procedure

To a stirred solution of compound 2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)-1-(1-trityl-1H-imidazol-5-yl)ethanol (400 mg, 0.69 mmol) in MeOH (10 mL), 1N HCl (1 mL) at 0° C. was added. The reaction mixture was stirred at RT for 2 h. The reaction mixture concentrated under vacuum to obtain the crude product that was basified with sat sodium bicarbonate solution and extracted with EtOAc (50 mL). The organic layer dried on anhydrous sodium sulfate, and concentrated under vacuum to obtain the crude product that was purified by reverse phase HPLC to obtain 1-(1H-imidazol-5-yl)-2-(10-methyl-2,3,5,6-tetrahydro-1H-indolizino[7,8-b]indol-7(11cH)-yl)ethanol (12 mg) as the TFA salt. 1H NMR (CD3OD, TFA salt) δ (ppm): 8.79 (s, 1H), 7.4 (s, 1H), 7.27 (s, 1H), 7.2 (dd, 1H), 7.01 (d, 1H), 5.18 (t, 1H), 5.04 (m, 1H), 4.39 (m, 2H), 3.67 (m, 3H), 3.42 (m, 2H), 3.2 (m, 1H), 2.7 (m, 1H), 2.4 (s, 3H), 2.2 (m, 3H). Separation by chiral HPLC provides diastereomers II-140a-d.

Workup

  1. concentrationThe reaction mixture concentrated under vacuum
  2. customto obtain the crude product that
  3. extractionextracted with EtOAc (50 mL)
  4. dry with materialThe organic layer dried on anhydrous sodium sulfate
  5. concentrationconcentrated under vacuum
  6. customto obtain the crude product that
  7. customwas purified by reverse phase HPLC

Sources & evidence

ORD record
ord-55817b15356249f6bf8155b7d4a6d4fb
Source dataset
uspto-grants-2015_04
Patent number
US09006263B2

Reaction notes

Loading…